Disclosures: Melissa Kaltenbach: Nothing to Disclose, David Kaplan: AstraZeneca Inc: Grant/Research Support, Roche Genentech: Independent Contractor, Exact Sciences: Grant/Research Support, Glycotest: Grant/Research Support, Sirtex: Advisor, Exelixis: Advisor, AstraZeneca: Advisor, Marina Serper: Transplant Genomics: Grant/Research Support, Grifols: Grant/Research Support, Eurofins: Grant/Research Support, Therese Bittermann: Nothing to Disclose 2218 DIGITAL PHENOTYPE VARIES BY ALCOHOL USE HISTORY AND HEPATIC ENCEPHALOPATHY Jessica Mellinger 1 Tingting Liu 2 Haila Asefa 3 Patricia Bloom 4 Sal Giorgi 2 Brenda Curtis 5 , 1 University of Michigan Hospitals and Health Centers, 2 Technology and Translational Research Unit, National Institute on Drug Abuse, 3 University of Michigan Hospitals and Health Center, 4 University of Michigan, Michigan Medicine, 5 National Institutes of Health Background: Hepatic encephalopathy (HE) is responsible for substantial cirrhosis-related burden and may be detectable by digital phenotyping

The Histone Deacetylase Inhibitor Sodium Butyrate Improves Insulin Signalling in Palmitate-Induced Insulin Resistance in L6 Rat Muscle Cells Through Epigenetically-Mediated Up-Regulation of Irs1
Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain
Experiment with light activity like stretching, yoga, or a walk after dinner to improve sleep depth
& Smith, S.R